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Abstract
The purpose of this paper is to better understand the methods problems and some solutions for siRNA treatments.
The benefits of this novel medical treatment are explored and its benefits are expounded on by comparing it to other
more complex and futuristic treatments. The exact process of siRNA silencing and down regulation is unknown. Some
hypotheses of how it may work are discussed giving precedence to the most widely accepted hypothesis. Although siRNA
treatments are not yet used on a major scale for many diseases, different possible treatment options are compared and
explained. Particular care was taken to give a broad range of illnesses in order to show the vast possibilities of siRNA
therapy. The common problems and some methods to overcome them are arranged in an orderly manner starting from
the time the siRNA treatment is administered, through its delivery and subsequent potency, followed finally by its degradation. SiRNAs viability as a treatment is then analyzed primarily on its large interest in many fields, as well as the enormous
progress it has made since its discovery just a short while ago.
Viability of SiRNA as a Clinical Treatment
The future of medicine is heading closer and closer to perfecting
gene therapy.While research is bringing the option to alter genes
closer to fruition, there is still a long way until it will be able to
be implemented. Simpler therapies albeit with their own set of
problems, seem to be a more realistic option for the foreseeable future. One in particular that has seen some progress is
the use of small interfering RNA (siRNA). ”Since its discovery
by Fire and Mellow in 1998, siRNA has proven to be a powerful
tool for modulating the expression of almost any gene in various
species.” (Nechaev, et al, 2013) During Göran Hansson’s speech
after receiving the noble prize for the discovery of a form of
RNA silencing, he said, referring to RNAi (more general term for
siRNA), that it “has added a new dimension to our understanding
of life and provided new tools for medicine.” (Eggleston, 2009).
It can have many applications and doesn’t necessarily require
the alteration of DNA. It allows the DNA to remain in its state
of disarray however it won’t allow the problematic gene to be
translated. This allows for control of the gene without having to
alter the DNA. The applications for this are countless. SiRNA
can treat many otherwise untreatable diseases ranging from viral
infections to complex genetic disorders (Endo-Takahashi. et al.
2012).Although the concept of siRNA is not a new one, there are
some kinks in how to use it as a treatment. One major setback
is that although it is now possible to create this aforementioned
silencing RNA (siRNA), its method of delivery is problematic.The
siRNA, if delivered indiscriminately, can wreak havoc in cells it
wasn’t intended for. It can stop crucial growth and functional elements of important life sustaining cells. It is therefore important
to deliver these potentially harmful substances only to their intended targets.This is just one of a few issues that can be a major
hindrance in siRNAs future as a treatment. It is imperative to
understand how siRNA works before an approach can be found
to tackle the issues that can arise in using siRNA as a treatment.
SiRNA silences the expression of specific genes allowing for particular cell functions to seize. SiRNA begins its life as a double
stranded RNA molecule (dsRNA). The dsRNA is cleaved into

shorter siRNAs. This process requires dicer to cleave the large
dsRNA. The siRNA is incorporated into a protein complex referred to as RNA inducing silencing complex (RISC). The still
double stranded siRNA is unwound by the protein complex via
multiple steps. The now single strand of siRNA leads the RISC to
the target RNA destroying it (Schwarz, et al, 2014).The destroyed
mRNA is no longer able to perform the function it was coded for.
This allows for a cell to continue with its other functions as long
as the specified protein isn’t crucial for the cells normal function.
The siRNA does not interact with the genome directly allowing
for less risk of creating mutant cells.

Possible Applications of siRNA
SiRNA has been studied largely for its application as a cancer
suppressor. It has however, many applications beyond that. whether in its ability to lower circulating cholesterol (Tep, et al, 2012)
by inhibiting the translation of a specific protein, or as a method
of controlling HIV-1(Zhou, et al, 2008) as well as possibly reducing any other potentially harmful protein synthesis. SiRNA can
have other non-clinical applications as well. Although the same
basic ideas and methods are used for all potential treatments
associated with siRNA the broad range of diseases it can potentially treat allows for some unique applications.
One study on the effects that siRNA can play in treating ovarian
cancer used a pretty classical method of using siRNA.The surface
protein cd44 is necessary in activating signal pathways necessary
for cancer, specifically metastasized, to continue its growth and
destruction. These pathways instruct the cell to continue transcribing proteins necessary for cell growth, as well as other factors that allow the cancer cells to live and multiply. The cd44
protein is also only found to be expressed by metastasized cancer cells, thus negating many of the issues associated with siRNA
delivery that will be discussed later.The study used siRNA as well
as an anticancer drug to see the combined effects they could
have on metastasized ovarian cancer. The siRNA was specific to
mRNA coding for cd44. It was carried out in vitro as well as in
vivo with similarly successful outcomes; the cancer cells growth
was slowed dramatically in both tests. Compared to just the use
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of the cancer drug and other chemotherapies, it was deemed
more efficient and aggressive. This is a truly great step forward
in finding a new cure with this rarely used method of treatment.
(Shah, et al, 2013).
SiRNAs use as a treatment for HIV is also being considered.“HIV1 gene expression, during productive and chronic infection, is essentially dependent upon the early regulatory genes tat and rav.”
(Caputo, et al, 1997) If a method to stop these regulatory genes
from being expressed can be found it can be used to virtually
control HIV. Although there have been many improvements in
controlling and preventing new outbreaks of HIV and the associated life altering conditions, HIV is still a still prolific disease(Centers for Disease Control, 2013) .
Working on this premise, researches created a siRNA delivery
method that is specific to the HIV strain they were interested in
controlling. The siRNA was manufactured to be specific to the
genes that coded for tat and rav. In stopping the expression of
these genes that are crucial for the viability of HIV-1 they were in
essence stopping the disease. Through methods including quantitative real time pcr, they were able to confirm that the genes
associated with rav and tat were significantly down regulated
(Zhou, et al, 2008).
The extensive range of treatments that can be possible with a
treatment involving siRNA doesn’t just apply to cases of cancer
and the HIV virus. It is being evaluated for its potential as a method of treating conditions involving an increased level of low density lipoprotein (LDL) cholesterol. “In individuals with 5-year risk
of major vascular events lower than 10%, each 1 mmol/L reduction in LDL cholesterol produced an absolute reduction in major
vascular events of about 11 per 1000 over 5 years” (Cholesterol
Treatment Trialists’ (CTT) Collaborators. 2012). A reduction in
ones LDL levels, specifically in the amount found in one’s blood
stream, has proven to reduce the risk of cardiovascular disease
(Manninen, et al, 1992), and might be a factor in lowering the risk
of those who have had a stroke previously from having another
(Sacco, et al, 2006) .
SiRNA can be used indirectly as a way to lower LDL cholesterol
levels. “ A novel therapeutic approach to lower LDL-c that is currently in clinical development involves blocking VLDL assembly
and secretion by inhibiting the microsomal triglyceride transfer
protein (Mtp)” (Tep, et al, 2012). By using siRNA to inhibit translation of the gene responsible for Mtp, they were able to reduce
the levels of LDL cholesterol found in the blood stream. This is
especially useful for those who don’t react well to the current
protocol set to reduce LDL levels by prescribing statins.
The broad range of application in a clinical sense for the use of
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siRNAs is apparent from the few studies mentioned. There are
many other applications that can be utilized, but those mentioned
here show how broad its ability as a drug can be. Most of these
studies however, are very theoretical. There are many hurdles
that must be overcome before being able to use it as a treatment.
The main hurdles being its delivery to a specific cell and stopping
a specific protein without affecting others.

Problems and Their Potential Answers
Delivery of SiRNA to cells has been a major problem for researchers. There are quite a few reasons that it is difficult to
deliver molecules of siRNA, or more specifically its precursor
dsRNA, to cells. The first is its really short lifespan. Even if the
dsRNA won’t degrade before reaching its desired location, the
trouble of getting it into the cytoplasm of the cell is a hurdle in
itself. However the biggest issue seems to be how to get these
crucial siRNAs to a specific cell. Once in the correct cell, problems may still arise. SiRNA can be finicky at times and down
regulate proteins that it wasn’t intended for. Basically the siRNA
has major issues with its specificity on the cellular level as well
as intercellular.
“Unmodified, naked siRNAs are relatively unstable in blood
and serum, as they are rapidly degraded by endo- and exonucleases, meaning that they have short half-lives in vivo.” (Akhtar,
Benter, 2007). This limits the ability to administer siRNAs in their
“naked” already modified form. However, chemically modifying
the siRNAs seems to prevent their untimely degradation. Studies
were done comparing siRNA in its naked, already modified form,
to siRNA that was chemically modified either by way of caging,
nanoparticles, or PEGylation. When this comparison was done
under conditions that simulated living in the blood stream, the
siRNA that had been modified showed a significant increase in
life span. Chemically modifying siRNA seems to be the way to
allow for the siRNA to survive its journey to the cell. (Shah, et
al 2013)
Surviving its journey to the cell is just the first of many hurdles
for this important new treatment. The next major stumbling
block to overcome is how to get it to the cell of choice. Although
siRNA is selective for specific proteins it can cause havoc in a cell
it wasn’t intended for. For example, even if a cell doesn’t have the
specific protein that this siRNA codes for it can cause unwanted mRNA degradation due to off targeting (B. Scaggiante, et al,
2011), a complication that will be discussed in a more general
sense in the coming paragraphs.
Some methods are being studied as ways to allow the delivery
to be more specific. The use of aptamers has been relatively successful in allowing the siRNA to reach specific cells, although it
has its own unique set of issues (Liu, Gao, 2013). Another method

Silent RNA as a clinical treatment

that has been used is connecting the siRNA enclosed in nanoparticles to an existing delivery system. This has shown promising
results especially when the intended drug is also used (Shah, et al,
2013). Other methods are showing promising results as well.This
leads to the next problem of the siRNA being delivered across
the cell membrane.
SiRNA can be especially difficult to deliver through the cell membrane due to its charge. The cell membrane has an affinity to
the siRNAs inherent charge causing it to be repelled. There are
several methods being studied to find the most efficient way of
allowing molecules of siRNA to penetrate the cell membrane.
The first is the physical or mechanical method. Using electroporation or ultrasound, for example, to allow for cellular uptake.
Another method being looked at is the use of chemicals either
to neutralize the negative charge of siRNA or deliver it through
other methods. (Zhou, et al, 2008)
With passage of siRNA through the cell now possible, off targeting, the last issue of delivery needs to be resolved. Although
siRNA is coded uniquely to suppress the desired protein, it isn’t
always so specific. If a similar protein is also produced in the cell
that the siRNA is delivered to, it can occasionally down regulate
that protein as well. A specific protein is one that has a similar
genetic code even though it can serve a very different and sometimes crucial role in the viability of the specified cell.
A few methods have been used to negate this off target silencing.
The methods mainly use modifications to the siRNA or dsRNA
starting material. By modifying the backbone of the strand, improved specificity was able to be reached. Although useful the
modifications tend to make the siRNA less efficient against the
target mRNA as well. There is one particularly successful option
that doesn’t affect the down regulation of the target mRNA as
much as many of the previous methods tried. This process requires adding a one nucleotide bulge on the antisense strand specifically at the second positon. The modified siRNA was found to
be more specific to the intended mRNA producing less mistaken
down regulation while still properly down regulating its intended
target. ( Dua, et al, 2011)
With its intended target found, the siRNA can now efficiently
down regulate it. However, the stable dsRNA that the RISC now
unwound to use as a mRNA inhibitor, is no longer as stable.
Due to its less stable state when joining the RISC, “Transfected
synthetic siRNA works for only a few days in mammalian cells.”
(Sioud 2004) While multiple treatments may reduce the issue of
short term effectiveness, a better solution may be available. Using
retroviral drugs the siRNA can be integrated into the genome
more specifically as hairpin RNA. This is like the naturally occurring non synthetic siRNA. Using siRNA the cell can regulate

itself post transcriptionally. By integrating the codons to produce
siRNA the time frame for siRNA longevity becomes indefinite.
This is not by it increasing in stability rather it allows for a constant dose without further intervention. (Stewart, et al, 2003)

Conclusion
The concept of using siRNA as a treatment for humans is one
that excites and can open many previously unavailable options
to those suffering many debilitating diseases. It is so promising
that any stumbling block that has arisen along the way hasn’t
deterred researchers from their final goal of using siRNA in the
clinical setting. They have attacked it from every angle and found
solutions for many problems and ideas for others.The main issue
of delivery primarily affects reaching specific cells or tissues with
specificity. There are clinical trials mainly focused on using siRNA
as a topical treatment. Although this method of treatment has
been proven successful, by eliminating many of the issues associated with delivery, it only works on areas that are able to react
to topical treatments. Topical siRNA treatments have seen much
progress and continue to pass multiple phases of their testing;
some have even been approved for clinical use. These treatments
bypass many of the issues discussed, and show the ability of
siRNA as a potential treatment for other diseases that need a
more complex delivery system.
The extensive opportunities for siRNA use are driving many to
discover new and improved methods. The way in which siRNA
has turned from a discovery into clinical trials in a mere fifteen
years attests to its great potential and likely future as a viable
treatment. There are many areas that are still unclear especially
regarding the methods in which siRNA works.With more discovery and new technology the methods of delivery and treatments
will likely improve and start the important work siRNA was intended for.
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